Committee members
- Quote...
-
"[TACT] comments highlighted relevant issues of the proposal and will surely help us to strengthen the final version of the project."
Professor Giuseppe Vita &
Dr Sonia Messina
University of Messina, Messina, Italy
Annamaria de Luca, as Chair, is leading this exciting initiative with the support of the core committee, nominated extended committee members and the TREAT-NMD secretariat.
In order to oversee the work of TACT on a regular basis and to provide guidance on its structure and content, a "core" group serves as a driver and common denominator of a broader membership.
Working closely with the Chair and core group are >70 additional international multidisciplinary experts, each with specific expertise in one or more of the areas of drug development. Such expertise include: discovery research, preclinical assessment of animal and cellular models, chemistry, preclinical pharmacology, formulation, toxicology, biostatistics, regulatory expertise in both the US and the EU, clinical care, clinical research, clinical development, clinical trial expertise, ethics, patient advocacy and funding of development programmes.
Core Committee
Annamaria de Luca - Committee Chair
Professor of Pharmacology - University of Bari
Annamaria is a pharmacologist specialized in pre-clinical in vivo and ex vivo studies of inherited and acquired neuromuscular disorders. In this general frame, she has a long lasting experience in preclinical research on pharmacological treatments for DMD and collaborates with leading scientists in the field.
Didier Caizergues - Regulatory Expert
Head of Regulatory Affairs and Quality Assurance - Généthon
Didier is a pharmacist specialised in Regulatory Affairs and also in product development. Since 2001 he has worked for GENETHON where he has successfully obtained Orphan Drugs designations and Clinical Trial Authorisations for gene therapy products in the field of NMD in several European countries.
James Dowling
Mogford Campbell family chair in paediatric neurosciences, Associate Professor of Paediatrics and Molecular Genetics - University of Toronto
Dr. Jim Dowling is a clinician-scientist focused on gene discovery and therapy development for childhood muscle diseases. He is a staff clinician and senior scientist at the Hospital for Sick Children as well as the Mogford Campbell family chair in paediatric neurosciences, and an Associate Professor of Paediatrics and Molecular Genetics at the University of Toronto.
Nathalie Goemans
M.D - UZ Leuven
Dr Nathalie Goemans (M.D. PhD) is a paediatrician and child neurologist, with certification in rehabilitation medicine and is currently head of the Neuromuscular Reference Centre within the department of Paediatrics and Child Neurology at the University Hospitals Leuven, Belgium, and consultant in neuropediatrics at DVC St Jozef Antwerp, Belgium, a rehabilitation centre with residential setting for neuromuscular patients.
Heather Gordish-Dressman
Associate Professor of Pediatrics
Dr. Gordish-Dressman is an Assistant Professor of Pediatrics at George Washington University School of Medicine and Health Sciences and the Center for Translational at Children's National Health System and is a statistician focusing on in neuromuscular diseases.
Miranda Grounds
Professor - University of Western Australia
Miranda has devoted over 30 years of research to better understanding the process of damage and repair of normal skeletal muscle.
Michael Kelly
Chief Scientific Officer - CureDuchenne
Dr. Michael Kelly is Chief Scientific Officer of CureDuchenne. Dr. Kelly, a senior pharmaceutical executive, brings more than 25 years of experience in drug discovery and development to the organization. He is responsible for advancing drug development programs and identifying new drug targets that exhibit potential to transform the treatment of Duchenne muscular dystrophy.
Anna Mayhew
Consultant Research Physiotherapist - Newcastle University
Dr Anna Mayhew is a Consultant Research Physiotherapist at The John Walton Muscular Dystrophy Research Centre at Newcastle, Newcastle University, UK. She has a special interest in development of robust and clinically relevant functional outcome measures for all types of neuromuscular disorders as well as suitable patient reported outcome measures.
Elizabeth McNally - Clinical Representative
Ward Professor and Director - Northwestern University Feinberg School of Medicine
Elizabeth McNally is Ward Professor and Director at Center for Genetic Medicine, Northwestern University Feinberg School of Medicine. Professor McNally has led preclinical and clinical research on inherited cardiovascular and neuromuscular diseases. Her expertise in the genetic mechanisms of cardiomyopathies and muscular dystrophies has led to new insight about how heart failure and muscle dysfunction occur.
Kathryn Wagner - Clinical expert/former chair
Professor of Neurology - The Johns Hopkins School of Medicine
Kathryn R. Wagner, M.D., Ph.D. is the Director of the Center for Genetic Muscle Disorders at the Kennedy Krieger Institute and Associate Professor of Neurology and Neuroscience at the Johns Hopkins School of Medicine. She treats patients with muscular dystrophies in a multidisciplinary clinic, addressing the multiple medical and social issues affecting these individuals and families.
Tracey Zoetis
Consultant for - SciLucent, LLC.
Tracey Zoetis, M.S. advises sponsors on regulatory and pharmacology/toxicology issues for FDA-regulated products, including pharmaceuticals, biologics, medical devices, and combination products. Her more than 25 years of experience in toxicology has afforded her a broad perspective on varied and interesting product safety issues. She has been employed by two major CROs, the FDA, and both large and small consulting firms.
Extended Committee
Annemieke Aartsma-Rus - Preclinical expert
Professor - Leiden University Medical Center
Dr. Annemieke Aartsma-Rus is a professor of translational genetics at the Department of Human Genetics of the Leiden University Medical Center and leader of the DMD genetic therapy group. She was previously Chair of the executive committee of the TREAT-NMD alliance, president-elect of the Oligonucleotide Therapeutics Society and is a member of the Project Ethics Council and TACT Committee.
Hugh Allen - Clinical Representative
Professor of pediatrics and medicine - Texas Childrens Hospital
Hugh's background is in echocardiography and cardiac function analysis, coupled with a large experience with the muscular dystrophy population. Presently he is a Professor of Paediatrics at Baylor College of Medicine, and is Staff Cardiologist at The Heart Center at Texas Children’s Hospital where he directs the care of neuromuscular cardiology patients.
Dimitrios Athanasiou - Patient Advocate
DMD Patient Advocate, UPPMD Board Member, EMA Patient Expert in DMD
Dimitrios Athanasiou holds a BA in Business Administration and an MBA in Financial Management. He speaks three European languages and has more than 25 years’ experience with international business projects, working in various countries in consulting, developing and reorganizing companies.
When his son was diagnosed with Duchenne Muscular Dystrophy, a fatal and incurable rare disease, he become a strong international patient advocate in Duchenne and Rare Diseases.
Having a passionate personality and technocratic background, he educated himself with basic rare disease and advocacy knowledge via the EURORDIS Summer School and then with the 14 month Patient Expert Course of the European Patient Academy of Therapeutic Innovation (EUPATI) acquiring basic biotech and regulatory knowledge, where he served as a Member of EUPATI’s Course Committee for the next year, representing the patient voice. Being a EUPATI fellow, he established the Greek EUPATI National Liaison Team.
Fabiola Bertinotti
Vice-president of FSHD Europe
Since Fabiola's adopted son was diagnosed with Facioscapulohumeral Muscular Dystrophy in 2005, Fabiola became deeply involved in the world of neuromuscular diseases. In Italy, Fabiola has been an active member of patient’s association Unione Lotta alle Distrofia Muscolare (UILDM), and has recently joined Coordinamento Associazioni Neuromusculari (CAMN).
At an international level, Fabiola is one of the founding members of FSHD EUROPE, a federation of local FSHD and other Muscular Dystrophy organizations whose main objective is to represent the interests of these European organizations in relation to their various international stakeholders. After serving for three years as president, during which the association expanded its reach to include various European FSHD and other Muscular Dystrophy local associations, Fabiola has been appointed Vice-president with specific focus on patient’s interests and TREAT-NMD. Fabiola is passionate about open science and co-creation and has enrolled into the EURORDIS Summer School program.
John Bourke - Clinical Representative
Consultant Cardiologist - Freeman Hospital
John graduated from the University College Dublin, Ireland in 1979. He is currently a Consultant Cardiologist (Electrophysiologist) at the Department of Cardiology, Freeman Hospital, Newcastle upon Tyne, UK, Senior Lecture at Newcastle University & an Associate Member of Institute of Human Genetics, International Centre for Life, Newcastle.
Arthur Burghes - Preclinical Expert
Professor - Ohio State University College of Medicine
Arthur completed his BS in Cellular & Microbial Biology in 1978 at the University of Calgary and his PhD in Biochemistry at University of London.
Gunnar Buyse - Preclinical Expert
Professor of Pediatrics & Pediatric Neurology - Universite Catholique de Louvain
Gunnar Buyse (MD, PhD) is Professor of Pediatrics and Child Neurology at the University of Leuven (Katholieke Universiteit Leuven), and is deputy clinical chair of Child Neurology at the University Hospitals Leuven. Gunnar Buyse is a Committee Member of the TREAT-NMD Advisory Committee for Therapeutics (TACT).
Donald Cairns - Medical Chemistry
Head of the School of Pharmacy and Life Sciences (PALS) - Robert Gordon University
Professor Donald Cairns obtained his Pharmacy degree and PhD from the University of Strathclyde. Following a year as a post-doctoral research fellow with the Cancer Research Campaign, Donald moved to Leicester Polytechnic where he held a five-year lectureship in pharmacy. In 1992 Donald was appointed senior lecturer in medicinal chemistry in Sunderland School of Pharmacy and in 2003 moved to Robert Gordon University in Aberdeen as Associate Head. In 2006, he was promoted to Professor of Pharmaceutical and Medicinal Chemistry, in 2010 he was appointed Acting Head of School and in 2012 he was appointed to his present post of Head of the School of Pharmacy and Life Sciences.
Paula Clemens - Clinical Representative
Professor of Neurology - University of Pittsburgh
Paula has a career-long interest in the muscular dystrophies spanning clinical care, basic research and clinical research endeavors. She is experienced as a site PI and study chair for studies conducted by the multi-center clinical trial network comprised of more than 25 centers worldwide, the Cooperative International Neuromuscular Research Group (CINRG).
Giulio Cossu - Clinical expert and cell therapy
Constance Thornley Professor of Regenerative Medicine
Giulio Cossu is Constance Thornley Professor of Regenerative Medicine at the University of Manchester. He received his MD degree from the University of Rome, then moved as Fogarty fellow at the University of Pennsylvania and in 1992 became Professor of Histology and Embryology in Rome. In 2000 he became Director of the Division of Regenerative Medicine at San Raffaele in Milan. In 2012 he moved as Professor of Human Stem Cell Biology to University College London and in 2013 to the University of Manchester.
He has been working as CAT member at EMA (2012-13). He is EMBO Member, Member of the European Academy of Science, Fellow of the Academy of Medical Sciences and of the Accademia dei Lincei. Giulio Cossu is recognized for his pioneering work on muscle development and on cell therapy for muscular dystrophies. He has published more than 200 peer-reviewed papers and secured grants for more than 10 M£.
Giulio Cossu has no conflict of interest to disclose.
Cristina Csimma - Drug development expert
Principal - Csimma LLC
Cristina Csimma’s experience in the biopharmaceutical, venture capital and academic settings encompasses global development in multiple therapeutic areas including rare neuromuscular diseases, translational through registration clinical studies, and integration of biomarkers and novel technologies into development as well as leadership roles in new company formation and fund raising. Dr Csimma served several years on the Core Committee and has reviewed many of our applications.
Simon Day - Regulatory and Statistical Expert
Independent consultant - based in the UK
Simon is a medical statistician with around 30 years’ experience working in clinical trials. He has worked in many different therapeutic areas and has been involved in academic-run studies as well as many carried out by the pharmaceutical industry. Apart from trial expertise, he also has a lot of experience in the overall drug-development process.
Beatrice de Montleau - Patient Organisation Representative
Board of Directors - Association Française contre les Myopathies - AFM
Beatrice de Montleau is the mother of three children, the youngest of whom is affected by Duchenne Muscular Dystrophy. Beatrice began her volunteer involvement with the AFM (French Muscular Dystrophy Association) by serving on the financial committee, bringing to that service a professional background in internal audit and sustainable development.
Marianne de Visser - Clinical Representative
Neurologist, Professor of Neuromuscular Disorders - Amsterdam Medical Centre
Marianne has been the leader of the neuromuscular group at the Academic Medical Centre in Amsterdam in the Netherlands for more than 20 years. During this time her group has contributed to research on muscular dystrophies, myositis, motor neuron diseases and hereditary neuropathies.
Sven Dittrich - Clinical Representative
Head of the Department of Pediatric Cardiology - Children's Hospital, University Hospital Erlangen
Prof. Sven Dittrich, MD is principal investigator of the German multicentric trial “Effect and Safety of preventive Treatment with ACE-Inhibitor and Beat-Blocker on the onset of Left Ventricular Dysfunction in Duchenne Muscular Dystrophy”, which is organized within the MD-Net and the German Competence Network for Congenital Heart Disease. His group also works on Tissue Doppler and cardiac MRI in Duchenne patients.
Alberto Dubrovsky - Clinical Representative
Director of Dept of Neurology and Director Neuromuscular Unit - Fundacion Favaloro Hospital Universitario
Alberto Dubrovsky, MD, is currently Director of the Department of Neurology, Director of Neuromuscular Disease Unit of the Neurosciences at Fundacion Favaloro. Since 1983 he has also served as Medical Director of the Argentina Muscular Dystrophy Association. Alberto is a Professor of Neurology at the University of Buenos and a Full Professor of Neurosciences at the Favaloro University, training as a Neurologist in the field of Neuromuscular Diseases at NIH under the sponsorship of W King Engel.
Gustavo Dziewczapolski
Scientific Director, Cure CMD
Dr. Dziewczapolski is the Scientific Director of Cure CMD. He plays the role of liaison between researchers, clinicians, pharma industry, patients and families with the aim of accelerating CMD research, diagnostics, care standards, and translation of research discoveries into real therapies.
Michelle Eagle - Physical Therapist Representative
Consultant Physiotherapist - Newcastle University
Michelle initially specialised in Rheumatology and gained a masters degree in the clinical evaluation and development of outcome measures in Ankylosing Spondylitis.
Kenneth Fischbeck - Preclinical Expert
Branch Chief - National Institute of Neurological Disorders and Stroke
Kurt is an NIH Distinguished Investigator and Chief of the Neurogenetics Branch at NINDS and a TREAT-NMD STAC member. He has experience with preclinical (animal) studies in various neuromuscular diseases including Duchenne muscular dystrophy, spinal muscular atrophy, and spinal and bulbar muscular atrophy (SBMA), and he has run clinical trials and biomarker studies in Duchenne muscular dystrophy, spinal muscular atrophy, Friedreich's ataxia, and SBMA.
Kevin Flanigan - Clinical Representative
Professor of Pediatrics and Neurology - Ohio State University College of Medicine
Kevin is the Director of the United Dystrophinopathy Project, an NIH-funded consortium studying the natural history and genotype/phenotype correlations in the DMD gene.
Pat Furlong - Patient Organisation Representative
CEO - Parent Project Muscular Dystrophy
Pat Furlong is the Founding President and CEO of Parent Project Muscular Dystrophy (PPMD) which she founded together with other parents of young men with Duchenne in 1994.
Nathalie Goemans - Clinical Representative
M.D - UZ Leuven
Dr Nathalie Goemans (M.D. PhD) is a paediatrician and child neurologist, with certification in rehabilitation medicine and is currently head of the Neuromuscular Reference Centre within the department of Paediatrics and Child Neurology at the University Hospitals Leuven, Belgium, and consultant in neuropediatrics at DVC St Jozef Antwerp, Belgium, a rehabilitation centre with residential setting for neuromuscular patients.
Heather Gordish-Dressman
Associate Professor of Pediatrics
Dr. Gordish-Dressman is an Assistant Professor of Pediatrics at George Washington University School of Medicine and Health Sciences and the Center for Translational at Children's National Health System and is a statistician focusing on in neuromuscular diseases.
Amelie Gubitz - Pre-clinical representative
Program Director at the National Institute of Neurological Disorders and Stroke
Amelie Gubitz serves as a Program Director at the National Institute of Neurological Disorders and Stroke (NINDS), USA. Her portfolio includes basic, translational and clinical research on amyotrophic lateral sclerosis, X-linked spinal and bulbar muscular atrophy, Friedreich's ataxia and hereditary spastic paraplegia. Amelie earned a Ph.D. in pharmacology from the University of Cambridge, UK, and then completed a Wellcome Trust Fellowship at Harvard Medical School. Subsequently, she worked as a Senior Scientist in the target discovery group for neuropathic pain at Parke Davis, UK. Prior to joining the NINDS in 2006, she studied the molecular pathogenesis of spinal muscular atrophy in the laboratory of Dr. Gideon Dreyfuss at the University of Pennsylvania.
Elin Haf Davies - Regulatory and clinical trial data expert
CEO, Aparito
Elin Haf Davies PhD is the CEO of Aparito, a company developed to support the adoption of technology and innovative solutions for monitoring patients in clinical trials and introducing innovative study designs, and data generation strategies. Prior to Aparito, Elin Haf has 18+ years of clinical, academic and regulatory drug development experience.
Jon Hastie - DMD Patient Representative
CEO, DMD Pathfinders
Dr Jon Hastie is the CEO of DMD Pathfinders, a user-led organisation of adults with Duchenne. He co-founded DMD Pathfinders in 2014 after working for several years on a transition programme for young people with Duchenne and has been a co-researcher on key social studies of adults with DMD. As an adult with Duchenne himself he has a detailed knowledge of the condition and its physical, social and psychological impacts in adulthood.
Eric Hoffman - Drug development
Director, Research Center for Genetic Medicine & The Wicker Project for Muscular Dystrophy Research - CINRG
Eric Hoffman, is Associate Dean for Research, School of Pharmaceutical Sciences, Binghamton University - SUNY, New York, USA and the CEO of ReveraGen BioPharma, Rockville, MD USA
Joseph Irwin - Ethical Input
Consultant - Lakeside Regulatory Consulting Services Ltd
Joseph Irwin became a Member of Spinal Muscular Atrophy Support UK (previously The Jennifer Trust for Spinal Muscular Atrophy) after his first son Toby was diagnosed with Type I SMA. Joseph, who is a biochemist-pharmacologist with molecular biology and cell biology experience, has worked for many years in hospital based research and for the pharmaceutical industry.
Jill Jarecki - Preclinical Expert
Research Director - Cure SMA
Jill is the Chief Scientific Officer at Cure SMA (formerly Families of SMA), and she has worked there since 2005. In this capacity, she has overseen over 40 million in SMA research investments, including in basic research, preclinical drug development, clinical research, and regulatory work.
Hermien Kan
Associate Professor - Leiden University Medical Center
Dr. Hermien E. Kan is staff member of the C.J. Gorter Center for high field MRI at the Leiden Universtiy Medical Center, where her main focus is on quantitiatve MR muscle and brain in Duchenne and Becker muscular dystrophy and high field muscle MR spectroscopy.
Petra Kaufmann - Clinical Representative
Director, Division of Clinical Innovation - NCATS
Petra Kaufmann, M.D., M.Sc., is Director of the Division of Clinical Innovation at the National Center for Advancing Translational Science (NCATS). In this capacity, she oversees the Clinical And Translational Science Award (CTSA) program, which supports a national consortium of medical research institutions working to transform the way biomedical research is conducted.
Oliver King - Statistician
Assistant Professor - University of Massachusetts Medical School
Dr Oliver King is an assistant professor in the Department of Neurology at the University of Massachusetts Medical School
Donald Kirsch - Research and Development / Drug Discovery Expert
Research and Development / Drug Discovery
Dr Donald Kirsch has almost 35 years of R&D leadership and management experience in the biopharmaceutical industry. He currently runs a biopharma consulting practice in Boston and New York, teaches Drug Discovery and Management at the Harvard University Extension School and courses at MassBio.
Rudolf Korinthenberg - Clinical Trial Coordination centre representative
Director, Neuropediatrics and Muscular Disorders - University Medical Center Freiburg
Prof. Rudolf Korinthenberg, MD is head of the Department of Neuropediatrics and Muscular Disorders at Children’s Hospital, University Hospital Freiburg. He received his pediatric and neuropediatric training at University Hospital Münster/Westfalia and holds his actual position since 1990.
Richard Lovering - Physical Therapist Representative
Associate Professor, Orthopaedics - University of Maryland - School of Medicine
Rich worked as a physical therapist starting in 1886. He returned to school and received his PhD in 2003, which was aimed at elucidating the cellular and molecular changes that occur during eccentric injury to muscle. He performed his post-doctoral work in the Department of Physiology at the University of Maryland (UMB) School of Medicine where he examined the role of intermediate filaments in skeletal muscle. There are many parallels in muscle that is injured, aging, or dystrophic; thus these are foci of work in the Lovering Laboratory. The Lab still maintains a strong interest in measuring muscle function (in vivo contractility) and relating the outcomes to changes at the cell level and to changes seen using non-invasive MR imaging and spectroscopy. The most recent efforts have been focused on elucidating the role of nuclear mobility, position, and function in dystrophic and aging muscles, and relating these findings to overall muscle function.
Linda Lowes - Physiotherapist
Director of Clinical Therapies Research - Nationwide Children's Hospital
Linda Lowes, PT, PhD is the director of clinical therapies research and a member of the Center for Gene Therapy at the Research Institute of Nationwide Children’s Hospital.
Oscar Henry Mayer - Clinical Representative
Medical Director, Pulmonary Function Testing Laboratory - Children's Hospital of Philadelphia
Dr. Oscar Henry Mayer is an Associate Professor of Clinical Pediatrics at The Perelman School of Medicine at the University of Pennsylvania, and an Attending Pulmonologist within the Division of Pulmonology at the Children’s Hospital of Philadelphia (CHOP), where he is the medical director of the CHOP Pulmonary Function Testing (PFT) laboratory.
Anna Mayhew - Physical Therapist Representative
Consultant Research Physiotherapist - Newcastle University
Dr Anna Mayhew is a Consultant Research Physiotherapist at The MRC Centre for Neuromuscular Diseases at Newcastle, Newcastle University.
John McCall - Toxicology Expert
President, PharMac LLC - PharMac LLC
John McCall’s expertise is drug discovery, risk minimization, and medicinal chemistry. He has worked in a number of disease areas including acute and chronic neurologic disorders, psychiatric diseases, neuromuscular disease, cardiovascular disease, inflammatory disease, and oncology. He is currently President, PharMac LLC. Dr McCall has served for several years on our Core Committee and has reviewed many of our applications.
D. Elizabeth McNeil - Regulatory Expert
National Institutes of Health - NIH
Dr. Elizabeth McNeil came to NINDS in 2010, after working for 8 years at the US Food and Drug Administration (FDA). While at the FDA, she worked extensively on a full range of products, including new molecular entities, new formulations of approved drug products, drug-drug combinations, and drug-device combinations. She worked to develop new scientific, clinical and regulatory standards for the development of certain drug classes and developed initiatives which resulted in standardization and clarification of terminology used in defining claims and endpoints, as well as in increased standardization, precision, and sensitivity in reporting safety and efficacy data.
Debra Miller
Founder and CEO - CureDuchenne
Debra Miller co-founded CureDuchenne in 2003 with her husband, Paul, after their only son was diagnosed with Duchenne. She relies on her extensive background in sales and marketing to lead CureDuchenne.
Jenny Morgan - Pre-clinical and stem cell expert
Professor
Jennifer Morgan is a Great Ormond Street Hospital Children’s Charity Professor of Cell Biology in the Dubowitz Neuromuscular Centre, Molecular Neurosciences Section, Developmental Neurosciences Programme, University College London Great Ormond Street Institute of Child Health. She is a member of the muscular dystrophy exon skipping (MDEX) consortium where she is involved in the analysis of dystrophin exon skipping and dystrophin protein production in cells and muscles of patients treated with antisense oligonucleotides in clinical trials. She is also a PI of the MRC Centre for Neuromuscular Diseases, a partnership between the UCL Institutes of Neurology and Child Health and the University of Newcastle upon Tyne, directed by Professor Michael Hanna at the UCL Institute of Neurology.
Wolfgang Müller-Felber
Associate Professor of neurology, Neurologist and psychiatrist, pediatric neurologist
Wolfgang Müller-Felber is a pediatric neurologist at the Dr. v. Hauner children‘s hospital at the university of Munich (LMU), Germany. He has a longstanding interest in neuromuscular disorders.
Francesco Muntoni - Clinical Representative
Director of The Dubowitz Neuromuscular Centre - University College London
Francesco Muntoni (Professor in Pediatric Neurology, FRCPCH, FMedSci) is Director of the Unit with oversight of both clinical and research activities.
Kanneboyina Nagaraju (Raju) - Preclinical Expert
Professor of Integrative Systems Biology and Pediatrics - Childrens National Health System
Kanneboyina Nagaraju, DVM, PhD is a principal investigator at the Research Center for Genetic Medicine, Children’s National Medical Center (CNMC) and a tenured associate professor of Integrative Systems Biology and Pediatrics at George Washington University School of Medicine and Health Sciences.
Ichizo Nishino
Director, Department of Neuromuscular Research - National Institute of Neuroscience - National Center of Neurology and Psychiatry
After having 5 years of clinical neurology training, Dr. Nishino started muscle disease research from 1994 under the tutelage of Dr. Ikuya Nonaka, who remained a steadfast source of inspiration. Later, his postdoctoral research for two years at Columbia University solidified his yearning to focus on research. In 2001, he was appointed directorship of the current Department of Neuromuscular Research and since then, he has been directing his team on the research to elucidate the pathomechanism and develop the therapy for hereditary muscle diseases, including DMRV/hIBM and various muscular dystrophies.
Marie-Christine Ouillade - Patient Organisation Representative
President of SMA Europe - Association Française contre les Myopathies - AFM
Marie-Christine is the mother of a young lady affected by SMA. She is president of SMA Europe an umbrella association of SMA patients organization in Europe She is also a member of AFM Board of Directors, and GENETHON board of directors.
Mike Pleiss - Pharmacology Expert
Pharmaceutical Research and Development Executive - Mike Pleiss and Associates, LLC
Mike was part of several project teams (and head of the multiple sclerosis (MS) / autoimmune effort) that resulted in several first-in-class therapeutics for Alzheimer’s (AD), MS and other autoimmune diseases.
John Porter - Preclinical expert and patient advocacy
Chief Science Officer, Myotonic Dystrophy Foundation
John Porter, Ph.D. is Chief Science officer for the Myotonic Dystrophy Foundation, a non-profit focused on improving patient care and developing novel therapies for myotonic dystrophy. He has a strong interest in ensuring the scientific rigor of preclinical study design, conduct, and the validity of data used to provide rationale for clinical trials, across all neuromuscular disorders, and played a key role in efforts to include such considerations in Federal and non-Federal grant review processes.
Christoph Rehmann-Sutter - Ethical Input
Professor of Theory and Ethics in the Biosciences - University of Lübeck
Christoph Rehmann-Sutter is a philosopher, Professor of Theory and Ethics in the Biosciences at the University of Lübeck in Germany and currently also Visiting Professor at King’s College in London. Born in 1959 he obtained a first training in molecular biology with a Diploma from the Biocenter at University of Basel in 1984, then a second full training in philosophy and sociology with a doctoral degree at the Technical University of Darmstadt 1995. 1997-1998 he joined the Department of Environmental Science, Policy and Management ESPM of the University of California at Berkeley as a Research Fellow. 1996-2009 he was Head of the Unit for Ethics in the Biosciences at the University of Basel in Switzerland. 2001-2009 he was Chair of the Swiss National Advisory Commission on Biomedical Ethics, elected by the Swiss Government, advising parliament and government.
Isabelle Richard
Généthon
Since her PhD studies in 1991, Isabelle has been working on Limb Girdle Muscular Dystrophies: identification of the genes and study of their protein functions to identify pharmacological solutions, development of animal models and investigation of gene transfer by gene therapy.
Urs Ruegg - Pharmacology Expert
Professor emeritus of Pharmacology - University of Geneva
After twelve years of drug research in the Basel pharmaceutical industry, Urs joined the University of Lausanne as Professor of Pharmacology in 1992. Since 2004 he has headed the Laboratory of Pharmacology at Geneva – Lausanne School of Pharmaceutical Sciences, University of Geneva. Since 1992, he has had full responsibility for the entire curriculum in pharmacology for pharmacy students.
Monique Ryan - Clinical Representative
Director, Neurology Department, The Royal Children's Hospital, Melbourne - The Royal Children's Hospital
Monique is a paediatric neurologist with a long interest into clinical research into the neuromuscular disorders of childhood. She has expertise in the design and performance of clinical trials - both into natural history and of pharmacotherapeutic agents - in muscle and nerve disorders of childhood, as well as a research interest into outcome measures (particularly neurophysiologic and functional measures). She is Director of the Neurology Department at The Royal Children's Hospital in Melbourne.
Lars Sandman - Ethics
Professor of Care Ethics - University of Boras
Professor Lars Sandman is a philosopher by training and received his PhD in practical philosophy from Gothenburg university in 2002. He is currently professor of care ethics at University of Borås, Sweden, and guest professor at the National Centre for Priority Setting in Health Care at Linköping University, Sweden.
Jeremy Shefner - Clinical Representative
Professor and Chair of Neurology - Upstate University Hospital
Jeremy Shefner, MD, PhD, is Chair of the Department of Neurology and Associate Director for Barrow Neurological Institute.
Lee Sweeney - Preclinical Expert
Professor and Chair of the Department of Physiology at Perelman School of Medicine of the University of Pennsylvania
H. Lee Sweeney, Ph.D., is the William Maul Measey Professor and Chair of the Department of Physiology at Perelman School of Medicine of the University of Pennsylvania. He is working to develop therapies for the skeletal and cardiac muscle aspects of muscular dystrophies using both small molecule and gene therapy approaches. Dr. Sweeney is the Director of a Wellstone Muscular Dystrophy Cooperative Research Center funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Ulrike Schara - Clinical Representative
MD - University of Essen
Ulrike Schara is a paediatric neurologist at the university hospital in Essen, Germany. She has a long-standing clinical interest in muscle disorders and CMS. She has recently started to build a patient registry for CMS in collaboration with TREAT-NMD.
Jeff Towbin - Clinical Representative
Professor and Chief, Pediatric Cardiology, Executive Co-Director The Heart Institute - Cincinnati Children's Hospital
Dr. Jeffrey A. Towbin, Executive Director of the Heart Institute and Professor & Chief, Pediatric Cardiology at Le Bonheur Children’s Hospital, St. Jude Children’s Research Hospital and the University of Tennessee Health Science Center in Memphis, did his Pediatric Residency at Children’s Hospital Medical Center in Cincinnati.
Jan Verschuuren - Clinical Representative
Head of Neuromuscular Section, Department of Neurology - Leiden University Medical Center
Jan Verschuuren is a neurologist and professor of Neuromuscular Disease at the LUMC. He is the clinical representative for the LUMC in TREAT-NMD, and president of the Dutch Neuromuscular Centre (www.ISNO.nl).
Maryze Schoneveld van de Linde - Patient expert - Pompe disease
On February 1, 2009 Maryze Schoneveld van der Linde joined the ENMC as project manager for TREAT-NMD. In 1995 Maryze Schoneveld van der Linde graduated with a masters degree in Cultural Anthropology at the University of Leiden. Since 1996 she has been working with migrant and refugee women from Turkey and the Middle East Region in empowerment related issues and activities.
Maryze Schoneveld van der Linde has been an active board member of the Dutch Association for Respiratory Support (VSCA, 1997 - 2006) and an active board member of the International Pompe Association (IPA, 1999 - 2006).
Currently she is advisor of the IPA. In 2007 she started a consultancy in health and care called Patient Centered Solutions. With her consultancy she provides clients with experienced based expertise, knowledge and practical insights from a patient's perspective regarding issues related to health and care.
Elizabeth Vroom - Patient Organisation Representative
Chair, World Duchenne Organisation (UPPMD)
Elizabeth is the president of Dutch Duchenne Parent Project and the chair of United Parent Projects Muscular Dystrophy (UPPMD). UPPMD is owned and managed by parent project organisations set up by parents of children with Duchenne Muscular Dystrophy in many different countries all over the world. As the chair of UPPMD, Elizabeth can represent the Duchenne parent community on the TACT committee.
Maggie Walter - Clinical Representative
Associate Professor of Neurology - Friedrich-Baur Institut, Ludwig-Maximilians University Munich
Maggie Walter is Associate Professor of Neurology at the Ludwig-Maximilians-University of Munich. She has trained as a neurologist at the LMU Munich, and is working at the Friedrich-Baur-Institute, the neuromuscular department of the LMU, in leading position. Furthermore, she graduated with a master degree in management of social and health institutions.
Dominic Wells - Preclinical Expert
Professor Neuromuscular Diseases Group - The Royal Veterinary College
After several years in general practice he moved to the USA and did his PhD on hummingbird flight. After that he returned to the UK with a lecturer post at the Royal Veterinary College where he first became involved in DMD research. From 1995 he has been based at the Imperial College.
Raffaella Willmann
TREAT-NMD activity coordinator - Swiss Foundation for Research on Muscle Diseases
Raffaella Willmann studied Biology in Italy and obtained her PhD in Biochemistry in Konstanz (Germany). After a first post-doc position in muscle physiology in Konstanz, she joined the group of Prof. Fuhrer in at the University of Zürich in 2000.
Since 2012, she is affiliated to the Swiss Foundation for Research on Muscle Diseases as scientific assistant.
Meg Winberg - Preclinical Expert
Independent consultant - based in the USA
In Meg’s former capacity as Director, Discovery Research at the Spinal Muscular Atrophy Foundation she has driven and overseen the Foundation’s efforts in the development and execution of new cell-based assays and drug screens and implementation of standardized drug testing in a mouse model of SMA.
Minal Jain
Research Coordinator
Minal Jain, PT, DSc, PCS is the research coordinator for the physical therapy section of the Rehabilitation Medicine Department at the NIH Clinical Center.
Secretariat
Kate Bushby - Secretariat
Professor of Neuromuscular Genetics - Newcastle University
Prof. Kate Bushby MD FRCP is a Professor of Neuromuscular Genetics. She is a clinical academic with joint appointments between Newcastle University and the NHS. The Muscle Team within the Institute of Genetic Medicine is a partner in the MRC Centre for Neuromuscular Diseases, of which Prof Bushby is Deputy Director.
Volker Straub - Secretariat
Professor of Neuromuscular Genetics - Newcastle University
Professor Volker Straub is joint co-ordinator of TREAT-NMD, executive board member of the World Muscle Society and executive board member of the Institute of Human Genetics at Newcastle University.
Joanne Lee - Secretariat
TACT Project Assistant
Joanne has worked with TREAT-NMD for some time and is involved in many activities in the Secretariat. She has had particular responsibilities for supporting the post-marketing Surveillance registry project, patient registries and conference organisation. Joanne also part of the TACT Secretariat based at Newcastle University and supports the administration of the review process and the organisation of the face-to-face meetings.
Cathy Turner - Secretariat
DMD Programme and TACT Coordinator - Newcastle University
Cathy Turner is Duchenne Programme and TACT Coordinator at the John Walton Muscular Dystrophy Research Centre. Cathy has also been responsible for supporting the NeurOmics project with significant involvement in communications, data-sharing and ethics. Prior to this she was the communications officer for BIO-NMD. In addition, Cathy works closely with patient organisations on improving patient and family involvement in neuromuscular research and is part of a small team currently developing interactive digital tools to support children taking part in paediatric clinical trials.
Cathy has a background in journal publishing with Elsevier Science and Emerald Insight and then worked as a science teacher for 5 years before joining the team here at Newcastle University. She has a degree in biochemistry, a post-graduate teaching certificate in science and a Masters in Business Administration.
Michael Hails
Web Development Officer - Newcastle University
Michael joined the TREAT-NMD team in March 2009 and is responsible for maintaining and developing the TREAT-NMD website.